HLB and group stocks hit the daily limit down one after another after the FDA rejected approval of rivoceranib
HLB said that the U.S. Food and Drug Administration (FDA) did not approve the new liver cancer drug 'rivoceranib' on 2026year 7month 10day. The company explained that the cause was a problem at its Chinese partner's production facility, and on the day of the announcement, HLB and affiliates hit the daily limit down.
HLB disclosed that the U.S. Food and Drug Administration (FDA) did not approve the new liver cancer drug 'rivoceranib' on 2026year 7month 10day, and it was reported that the reason was a problem at the Chinese partner's production facility.
On the news, HLB and group affiliates plunged in early trading and hit the daily limit down. HLB fell by 1ten thousand 5600won from the previous session.
Immediately after trading began, investors dumped sell orders, and many stocks fell to the limit-down level across all issues. The number of limit-down issues by specific affiliate was shown in disclosures and trading trends.
The company said manufacturing-related issues were the reason the approval was not granted. It was reported that there were concerns over the suitability of the production facility operated by its Chinese partner.
The detailed reasons for the FDA’s decision and the specific follow-up requirements have not yet been announced. The related companies may issue additional disclosures and response plans for regulatory action.
During Korean time 7month 10day, this decision delivered a direct blow to HLB’s share price and trading. Investors are watching the company’s disclosures and trading trends.